Ignite Creation Date:
2025-12-26 @ 10:36 AM
Ignite Modification Date:
2025-12-29 @ 2:13 PM
Study NCT ID:
NCT05507528
Status:
COMPLETED
Last Update Posted:
2024-02-15
First Post:
2022-08-17
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Evaluation of the Safety and Efficacy of REBORN System for Lipolysis Treatment
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP', 'interventionModelDescription': 'open label, prospective, single arm, interventional study'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 107}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2022-06-30', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-02', 'completionDateStruct': {'date': '2023-11-11', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-02-14', 'studyFirstSubmitDate': '2022-08-17', 'studyFirstSubmitQcDate': '2022-08-17', 'lastUpdatePostDateStruct': {'date': '2024-02-15', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2022-08-19', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-11-11', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Fat reduction', 'timeFrame': '20 weeks', 'description': 'to demonstrate fat reduction in the treated area after treatment with the ReBorn LED system.'}, {'measure': 'Blinded reviewers evaluation', 'timeFrame': '20 weeks', 'description': 'subject\'s pre and post-treatment photographs will be presented in randomized order to blinded reviewers for evaluation.\n\nSubject is considered "success" if at least two out of the three evaluators correctly identify photographs order.'}], 'secondaryOutcomes': [{'measure': 'safety evaluation', 'timeFrame': '20 weeks', 'description': 'The safety of the ReBorn LED System will be demonstrated by serious adverse event during the study.'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': True}, 'conditionsModule': {'conditions': ['LIPOLYSIS']}, 'descriptionModule': {'briefSummary': 'The Lightfective ReBorn System is intended for non-invasive lipolysis of the flanks in individuals with a Body Mass Index (BMI) of 30 or less. The device is intended to affect the appearance of visible fat bulges in the flanks.', 'detailedDescription': "Body countering and fat reduction treatment are considered to be one of the most popular aesthetic procedures. The Lightfective' ReBorn LED System provides non-invasive fat reduction treatment.\n\nThe primary efficacy objective is to demonstrate fat reduction in the treated area after treatment with the ReBorn LED system.\n\nstudy population, Healthy subjects who seek for fat reduction treatments in the flanks area.\n\nEach subject will undergo 2 treatment visits (one month apart) and follow-up visits."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '22 Years', 'healthyVolunteers': True, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. Male or female subjects \\> 22 years of age.\n2. Subject has clearly visible fat on the flanks area.\n3. Subject has not experienced weight change exceeding 4.5kg in the preceding month.\n4. Subject agrees to maintain their weight (i.e., within 2.25kg) by not making any major changes in their diet or lifestyle during the course of the study.\n5. Subject is willing and able to comply with protocol requirements and all study visits\n6. Subject has provided a written informed consent\n\nExclusion Criteria:\n\n1. Subject underwent a prior surgical procedure(s) in the area of intended treatment within the past 6 months.\n2. Subject underwent a prior invasive fat reduction procedure (e.g., liposuction, abdominoplasty, mesotherapy) in the area of intended treatment within the past year.\n3. Subject underwent a prior non-invasive fat reduction procedure in the area of intended treatment within the past 6 months.\n4. Subject has a known history of subcutaneous injections into the area of intended treatment (e.g., clexane, insulin) within the past month.\n5. Subject has a known history of cryoglobulinemia, cold urticaria, or paroxysmal cold hemoglobinuria.\n6. Subject has a known history of Reynaud's disease, or any known condition with a response to cold exposure that limits blood flow to the skin.\n7. Subject has a history of bleeding disorder, or is taking any medication that in the investigator's opinion may increase the subject's risk of bruising.\n8. Subject body mass index (BMI) exceeds 30. BMI is defined as weight in kg divided by the square of the height in cm.\n9. Subject is taking or has taken diet pills or supplements within the past month.\n10. Subject has any dermatological conditions or scars in the location of the treatment sites that may interfere with the treatment or evaluation.\n11. Subject is pregnant or intending to become pregnant in the next 6 months.\n12. Subject is lactating or has been lactating in the past 6 months.\n13. Subject is unable or unwilling to comply with the study requirements.\n14. Subject is currently enrolled in a clinical study of any other unapproved investigational drug or device.\n15. Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.\n16. Subject is currently taking weight reduction medications (e.g., Saxenda).\n17. Subject is currently taking GLP-1 receptor agonist medications (e.g., Victoza)."}, 'identificationModule': {'nctId': 'NCT05507528', 'briefTitle': 'Evaluation of the Safety and Efficacy of REBORN System for Lipolysis Treatment', 'organization': {'class': 'INDUSTRY', 'fullName': 'Lightfective Ltd'}, 'officialTitle': 'EVALUATION OF THE SAFETY AND EFFICACY OF REBORN LED SYSTEM FOR NON-INVASIVE LIPOLYSIS TREATMENT', 'orgStudyIdInfo': {'id': 'RB-LF-01'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Reborn treatment group', 'description': 'The Lightfective ReBorn System is a Diode Light Emitting Diode (LED) System, Fat reduction treatments with the ReBorn LED System visit - include the treatment procedure', 'interventionNames': ['Device: reborn treatment']}], 'interventions': [{'name': 'reborn treatment', 'type': 'DEVICE', 'description': 'Fat reduction treatments with the ReBorn LED System visit - include the treatment procedure', 'armGroupLabels': ['Reborn treatment group']}]}, 'contactsLocationsModule': {'locations': [{'zip': '37215', 'city': 'Tennessee City', 'state': 'Tennessee', 'country': 'United States', 'facility': 'Tennessee Clinical Research Center', 'geoPoint': {'lat': 36.09312, 'lon': -87.51474}}, {'zip': '3501261', 'city': 'Kiryat Bialik', 'country': 'Israel', 'facility': 'Herzelia Medical Center - Tal Nachliely clinic', 'geoPoint': {'lat': 32.8275, 'lon': 35.08583}}, {'zip': '49100', 'city': 'Petah Tikva', 'country': 'Israel', 'facility': 'rabin medical center - campus Hasharon', 'geoPoint': {'lat': 32.08707, 'lon': 34.88747}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Lightfective Ltd', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}